Updates are available Correction dated 2024-12-03
Click to view Correction: https://doi.org/10.1038/s41375-024-02487-1
-
Authors
Sharman, Jeff P. https://orcid.org/0000-0001-5611-6115
Egyed, Miklos
Jurczak, Wojciech https://orcid.org/0000-0003-1879-8084
Skarbnik, Alan
Pagel, John M. https://orcid.org/0000-0001-5745-8125
Flinn, Ian W. https://orcid.org/0000-0001-6724-290X
Kamdar, Manali
Munir, Talha
Walewska, Renata
Corbett, Gillian
Fogliatto, Laura Maria
Herishanu, Yair
Banerji, Versha
Coutre, Steven https://orcid.org/0000-0001-8420-5748
Follows, George
Walker, Patricia
Karlsson, Karin
Ghia, Paolo https://orcid.org/0000-0003-3750-7342
Janssens, Ann
Cymbalista, Florence
Woyach, Jennifer A. https://orcid.org/0000-0002-3403-9144
Ferrant, Emmanuelle
Wierda, William G. https://orcid.org/0000-0002-7357-270X
Munugalavadla, Veerendra
Yu, Ting
Wang, Min Hui
Byrd, John C.
-
Funding
Funding for this research was provided by:
Acerta Pharma, a member of the AstraZeneca group
- License Information
-
More Information
Article History
Received: 19 August 2021
Revised: 15 November 2021
Accepted: 17 November 2021
First Online: 1 January 2022
Change Date: 12 May 2022
Change Type: Update
Change Details: The original online version of this article was revised: The wrong Supplementary file was originally published with this article; it has now been replaced with the correct file. The original article has been corrected.
Change Date: 3 December 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41375-024-02487-1
Competing interests
: JS: Research funding from Seattle Genetics; research funding and consulting from AbbVie, AstraZeneca, BeiGene, BMS, Genentech, Gilead, Lilly, Pharmacyclics, TG Therapeutics; scientific board for Centessa; employment from US Oncology. ME: Nothing to disclose. WJ: Research funding from AstraZeneca, Janssen, and Loxo. AS: Consulting fees from AbbVie, AstraZeneca, Celgene, Genentech, GenMab, Kite, MorphoSys, Novartis, Pharmacyclics, Janssen, Alexion, Seattle Genetics, and TG Therapeutics; honoraria from AbbVie, AstraZeneca, BeiGene, Celgene, Genentech, Jazz Pharmaceuticals, Kite, Seattle Genetics, Pharmacyclics, Janssen, and TG Therapeutics; data safety monitoring board/advisory board participation for Alexion. JP: Consulting and speaker bureau for AstraZeneca. IF: Consulting fees from AbbVie, AstraZeneca, BeiGene, Genentech, Gilead, Great Point Partners, Iksuda, Janssen, Juno, Kite, MorphoSys, Nurix, Pharmacyclics, Roche, Seattle Genetics, Takeda, TG Therapeutics, Unum, Verastem, and Yingli; grants from AbbVie, Acerta, Agios, ArQule, AstraZeneca, BeiGene, Calithera, Celgene, Constellation, Curis, Forma, Forty Seven, Genentech, Gilead, IGM Biosciences, Incyte, Infinity, Janssen, Juno, Karyopharm, Kite, Loxo, Merck, MorphoSys, Novartis, Pfizer, Pharmacyclics, Portola, Rhizen, Roche, Seattle Genetics, Takeda, Teva, TG Therapeutics, Trilium, Triphase, Unum, and Verastem. MK: Research support/funding from TG Therapeutics and Genentech; consulting for AbbVie, Karyopharm, Kite, AstraZeneca, Celgene/Bristol Myers Squibb, Adaptive, and ADC Therapeutics; speaker’s bureau for Seagen; data monitoring committee member for Celgene and Genentech. TM: Consulting/advisory role for Morphosys, Sunesis, AstraZeneca, Janssen; honoraria from Janssen, AstraZeneca, Gilead, and Novartis. RW: Nothing to disclose. GC: Nothing to disclose. LMF: Nothing to disclose. YH: Honoraria from AbbVie, Janssen, AstraZeneca, and Roche. VB: Honoraria from AbbVie, Janssen, and AstraZeneca; grant funding from the Canadian Institutes of Health Research, Leukemia Lymphoma Society of Canada, CancerCare Manitoba Foundation, and the Hairy Cell Leukemia Foundation. SC: Honoraria from Janssen Oncology and Pharmacyclics; consulting for AbbVie, Adaptive Biotechnologies, AstraZeneca, BeiGene, Genentech/Roche, Janssen Oncology, and Pharmacyclics; clinical research support from AbbVie, Acerta Pharma/AstraZeneca, Janssen Oncology, Pharmacyclics; expert testimony for Genentech. GF: Consulting fees from AstraZeneca, Roche, AbbVie, Janssen, Karyopharm, Bristol Myers Squibb, and Centessa; honoraria from AstraZeneca, Roche, AbbVie, and Janssen; travel support from Roche, Janssen, and Bristol Myers Squibb. PW: Travel support from Roche; honoraria from AstraZeneca. KK: Nothing to disclose. PG: Honoraria from AbbVie, AstraZeneca, ArQule/MSD, BeiGene, Janssen, Loxo/Lilly, and Roche; research support from AbbVie, AstraZeneca, Janssen, and Sunesis. AJ: Consulting fees from Janssen, Roche, Gilead, AbbVie, Novartis, Amgen, Sanofi-Genzyme, and AstraZeneca; honoraria from Janssen, Roche, AbbVie, Novartis, Amgen, AstraZeneca, and BeiGene; travel support from AbbVie, Roche, Amgen, and Bristol Myers Squibb/Celgene. FC: Consulting fees from AbbVie; honoraria from Roche, AbbVie, AstraZeneca, and Janssen; travel support from AstraZeneca, Roche, and AbbVie. JW: Consulting for AbbVie, Janssen, Pharmacyclics, BeiGene, AstraZeneca, ArQule, and Loxo; research support from Loxo and AbbVie; clinical trial support from Karyopharm, Morphosys, Pharmacyclics, and Janssen. EF: Honoraria from Janssen-Cilag; payment for expert testimony from Gilead, AbbVie, and Janssen-Cilag. WW: Grants/contracts from GSK/Novartis, AbbVie, Genentech, Pharmacyclics, AstraZeneca/Acerta, Gilead, Juno, Kite, Sunesis, Miragen, Oncternal, Cyclacel, Loxo, Janssen, and Xencor. VM: Stock from and employment by AstraZeneca; family member association with Gilead. TY: Employment by AstraZeneca; stock from AstraZeneca, Johnson & Johnson, and AbbVie. MHW: Stock from and employment by AstraZeneca. JB: Stock and other ownership interests from Vincerx; honoraria from Pharmacyclics, AstraZeneca, Novartis, Syndax, and Trillium; consulting or advisory role for Acerta, Janssen, Kura, Novartis, Syndax, and AstraZeneca; research funding from Acerta, Pharmacyclics, and Zencor; patents, royalties, and other intellectual property from OSU Patents; travel support from Gilead, Janssen, Novartis, Pharmacyclics, and TG Therapeutics.
